Compare CNO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNO | SLNO |
|---|---|---|
| Founded | 1979 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.5B |
| IPO Year | 1987 | 2014 |
| Metric | CNO | SLNO |
|---|---|---|
| Price | $40.30 | $51.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $43.60 | ★ $110.90 |
| AVG Volume (30 Days) | 604.2K | ★ 1.8M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 20.08 | N/A |
| EPS | ★ 2.98 | N/A |
| Revenue | ★ $4,441,500,000.00 | $98,675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.57 | $155.86 |
| P/E Ratio | $13.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.63 | $41.50 |
| 52 Week High | $43.20 | $90.32 |
| Indicator | CNO | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 48.33 |
| Support Level | $40.03 | $47.80 |
| Resistance Level | $40.71 | $53.10 |
| Average True Range (ATR) | 0.80 | 2.47 |
| MACD | -0.09 | 1.09 |
| Stochastic Oscillator | 30.26 | 79.48 |
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.